Latest news

• AZ expects return to growth this year after 2017 decline

  to $2.6bn, although the cumulative effect of patent expiries - which also affect antipsychotic Seroquel XR (quetiapine) and gastrointestinal drug Nexium (esomeprazole) - are starting to dissipate.

• AZ CEO says company’s renaissance is on track

  for cholesterol drug Crestor (rosuvastatin) and antipsychotic Seroquel XR (quetiapine).

• US appeals court upholds AstraZeneca’s Seroquel XR patent

  US appeals court upholds AstraZeneca’ s Seroquel XR patent. Says patent on unique formulation of antidepressant is valid. ... But it isn't just Seroquel XR that AZ is trying to prolong the life of.

• AZ sees Seroquel XR patent overturned in Germany

  AZ sees Seroquel XR patent overturned in Germany. Follows challenge by Teva, Hexal and Accord Healthcare. ... Teva, Hexal and Accord Healthcare successfully persuaded the court to strike out the formulation patent protecting Seroquel XR (quetiapine

• New CEO says AZ open to acquisitions to rebuild pipeline

  Loss of patent protection for antipsychotic drug Seroquel IR (quetiapine) in the US was the major drag on its third-quarter results, with sales sliding to $169m from $1.03bn a ... Longer-acting Seroquel XR held up better, managing an 8 per cent gain to